Search research articles
Contact Us
Filters
Showing results (41-50 of 66) with videos related to
Page
of 7
Sort By:
Journal of Neurology
|
April 9, 2018
Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
E C Tallantyre, D H Whittam, S Jolles, et al.
Epidemiologie, Mikrobiologie, Imunologie : Casopis Spolecnosti Pro Epidemiologii a Mikrobiologii Ceske Lekarske Spolecnosti J.E. Purkyne
|
January 13, 2017
[Recurrent meningitis and inherited complement deficiency]
A Šrotová, J Litzman, Š Rumlarová, et al.
Journal of the American Academy of Dermatology
|
July 20, 2000
Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)
R K Lister, S Jolles, S Whittaker, et al.
Clinical and Experimental Immunology
|
August 20, 2015
Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations
M Ponsford, E Carne, C Kingdon, et al.
Pathology
|
May 19, 2001
The application of a PCR technique for the detection of immunoglobulin heavy chain gene rearrangements in fresh or paraffin-embedded skin tissue
J Hughes, S Weston, B Bennetts, et al.
Clinical and Experimental Immunology
|
August 4, 2022
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
S Grigoriadou, R Clubbe, T Garcez, et al.
Clinical and Experimental Immunology
|
February 7, 2019
British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders
C Bethune, W Egner, T Garcez, et al.
Clinical and Experimental Immunology
|
September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
M Borte, G Kriván, B Derfalvi, et al.
Clinical and Experimental Immunology
|
July 11, 2012
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
J S Orange, B H Belohradsky, M Berger, et al.
Clinical and Experimental Immunology
|
May 3, 2014
Calculated globulin (CG) as a screening test for antibody deficiency
S Jolles, R Borrell, S Zouwail, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 66) with videos related to
Sort By:
Page
of 7
Journal of Neurology
|
April 9, 2018
Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
E C Tallantyre, D H Whittam, S Jolles, et al.
Epidemiologie, Mikrobiologie, Imunologie : Casopis Spolecnosti Pro Epidemiologii a Mikrobiologii Ceske Lekarske Spolecnosti J.E. Purkyne
|
January 13, 2017
[Recurrent meningitis and inherited complement deficiency]
A Šrotová, J Litzman, Š Rumlarová, et al.
Journal of the American Academy of Dermatology
|
July 20, 2000
Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)
R K Lister, S Jolles, S Whittaker, et al.
Clinical and Experimental Immunology
|
August 20, 2015
Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations
M Ponsford, E Carne, C Kingdon, et al.
Pathology
|
May 19, 2001
The application of a PCR technique for the detection of immunoglobulin heavy chain gene rearrangements in fresh or paraffin-embedded skin tissue
J Hughes, S Weston, B Bennetts, et al.
Clinical and Experimental Immunology
|
August 4, 2022
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
S Grigoriadou, R Clubbe, T Garcez, et al.
Clinical and Experimental Immunology
|
February 7, 2019
British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders
C Bethune, W Egner, T Garcez, et al.
Clinical and Experimental Immunology
|
September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
M Borte, G Kriván, B Derfalvi, et al.
Clinical and Experimental Immunology
|
July 11, 2012
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
J S Orange, B H Belohradsky, M Berger, et al.
Clinical and Experimental Immunology
|
May 3, 2014
Calculated globulin (CG) as a screening test for antibody deficiency
S Jolles, R Borrell, S Zouwail, et al.
Page
of 7